NCT00004688 2015-03-25
Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
FDA Office of Orphan Products Development
Phase 2 Completed
FDA Office of Orphan Products Development
Hoffmann-La Roche
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)